TR199700656T1 - Guanin derivatlar�. - Google Patents

Guanin derivatlar�.

Info

Publication number
TR199700656T1
TR199700656T1 TR97/00656T TR9700656T TR199700656T1 TR 199700656 T1 TR199700656 T1 TR 199700656T1 TR 97/00656 T TR97/00656 T TR 97/00656T TR 9700656 T TR9700656 T TR 9700656T TR 199700656 T1 TR199700656 T1 TR 199700656T1
Authority
TR
Turkey
Prior art keywords
guanine
derivative
hydrochloride
purin
dihydro
Prior art date
Application number
TR97/00656T
Other languages
English (en)
Turkish (tr)
Inventor
Howard Carter Barry
Muse Partin Jane
Gregory Varlashkin Peter
Augustus Winnike Richard
Bayne Grubb William Iii
Alan Conway Gregory
George Lake Philip
Michael Skinner David
James Whatrup David
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199700656(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of TR199700656T1 publication Critical patent/TR199700656T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
TR97/00656T 1995-01-20 1996-01-19 Guanin derivatlar�. TR199700656T1 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative

Publications (1)

Publication Number Publication Date
TR199700656T1 true TR199700656T1 (xx) 1998-03-21

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
TR97/00656T TR199700656T1 (xx) 1995-01-20 1996-01-19 Guanin derivatlar�.

Country Status (40)

Country Link
US (1) US6107302A (instruction)
EP (1) EP0804436B1 (instruction)
JP (1) JP3176633B2 (instruction)
KR (1) KR100376074B1 (instruction)
CN (1) CN1049893C (instruction)
AP (1) AP662A (instruction)
AR (1) AR002270A1 (instruction)
AT (1) ATE302777T1 (instruction)
AU (1) AU702794B2 (instruction)
BG (1) BG63393B1 (instruction)
BR (1) BR9606768A (instruction)
CA (1) CA2210799C (instruction)
CY (1) CY2531B1 (instruction)
CZ (1) CZ297065B6 (instruction)
DE (1) DE69635106T2 (instruction)
DK (1) DK0804436T3 (instruction)
EA (1) EA000364B1 (instruction)
EE (1) EE03528B1 (instruction)
ES (1) ES2248806T3 (instruction)
FI (1) FI973063A7 (instruction)
GB (1) GB9501178D0 (instruction)
GE (1) GEP20001940B (instruction)
HR (1) HRP960024B1 (instruction)
HU (1) HU222993B1 (instruction)
IL (1) IL116831A (instruction)
IN (1) IN182468B (instruction)
IS (1) IS2268B (instruction)
NO (1) NO315558B1 (instruction)
NZ (1) NZ298851A (instruction)
OA (1) OA10499A (instruction)
PL (1) PL182175B1 (instruction)
RO (1) RO118693B1 (instruction)
RS (1) RS49518B (instruction)
SI (1) SI0804436T1 (instruction)
SK (1) SK285329B6 (instruction)
TR (1) TR199700656T1 (instruction)
UA (1) UA46001C2 (instruction)
UY (1) UY25779A1 (instruction)
WO (1) WO1996022291A1 (instruction)
ZA (1) ZA96449B (instruction)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
ATE254463T1 (de) * 1996-01-19 2003-12-15 Glaxo Group Ltd Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
CA2278474A1 (en) * 1997-01-17 1998-07-23 Ajinomoto Co., Inc. Novel z-valacyclovir crystals
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
EP1953162B9 (de) * 2001-02-24 2012-10-31 Boehringer Ingelheim Pharma GmbH & Co. KG Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
JP5043286B2 (ja) * 2001-09-07 2012-10-10 テバ ファーマシューティカル インダストリーズ リミティド バラシクロビル塩酸塩の結晶型
US20040197396A1 (en) * 2001-11-05 2004-10-07 Fain Helen S Anhydrous crystal form of valaciclovir hydrochloride
PL371732A1 (en) * 2001-11-14 2005-06-27 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
EP1517678A2 (en) * 2002-06-24 2005-03-30 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
TW200510414A (en) * 2003-06-02 2005-03-16 Teva Pharma Novel crystalline forms of valacyclovir hydrochloride
US20050192296A1 (en) * 2004-01-21 2005-09-01 Zvi Harel Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
JP2008504255A (ja) * 2004-06-30 2008-02-14 テバ ファーマシューティカル インダストリーズ リミティド 結晶塩酸バラシクロビル中の残留アルコールを低減する方法
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ES2379804T3 (es) * 2005-05-25 2012-05-03 Eli Lilly And Company Ésteres de ciclopropanocarboxilato de aciclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2016079A1 (de) 2006-05-04 2009-01-21 Boehringer Ingelheim International GmbH Polymorphe
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
JP5769966B2 (ja) * 2007-08-17 2015-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆａｂ関連疾患治療用プリン誘導体
WO2009031576A1 (ja) * 2007-09-03 2009-03-12 Ajinomoto Co., Inc. バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
ES2764251T3 (es) * 2008-08-15 2020-06-02 Boehringer Ingelheim Int Inhibidores de DPP-4 para uso en el tratamiento de curación de heridas en pacientes diabéticos
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
EP3366304B1 (en) 2010-06-24 2020-05-13 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US20140296520A1 (en) * 2011-11-25 2014-10-02 Piramal Enterprises Limited Process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
DE69426880T2 (de) * 1993-06-10 2001-10-31 Rolabo S.L., Zaragoza Verfahren zur herstellung von aminosäureester von nukleosid analogen
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
ES2248806T3 (es) 2006-03-16
NO973326L (no) 1997-09-16
EP0804436A1 (en) 1997-11-05
CZ297065B6 (cs) 2006-08-16
PL321326A1 (en) 1997-12-08
MX9705462A (es) 1997-10-31
RS49518B (sr) 2006-10-27
IN182468B (instruction) 1999-04-17
HUP9801836A3 (en) 1999-06-28
AU4453996A (en) 1996-08-07
PL182175B1 (pl) 2001-11-30
FI973063L (fi) 1997-09-18
FI973063A7 (fi) 1997-09-18
HRP960024B1 (en) 2005-08-31
KR19980701525A (ko) 1998-05-15
BG101833A (bg) 1998-04-30
NZ298851A (en) 1999-01-28
IS2268B (is) 2007-07-15
FI973063A0 (fi) 1997-07-18
EA199700124A1 (ru) 1997-12-30
JPH11503718A (ja) 1999-03-30
CY2531B1 (en) 2006-04-12
OA10499A (en) 2002-04-10
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
DK0804436T3 (da) 2005-12-27
EE9700175A (et) 1998-02-16
YU3396A (sh) 1998-12-23
US6107302A (en) 2000-08-22
GEP20001940B (en) 2000-02-05
GB9501178D0 (en) 1995-03-08
BR9606768A (pt) 1997-12-30
CZ229497A3 (en) 1997-12-17
SK96597A3 (en) 1998-02-04
ZA96449B (en) 1996-08-07
DE69635106D1 (de) 2005-09-29
RO118693B1 (ro) 2003-09-30
EE03528B1 (et) 2001-10-15
IS4527A (is) 1997-07-15
JP3176633B2 (ja) 2001-06-18
AP9701058A0 (en) 1997-10-31
HUP9801836A2 (hu) 1999-05-28
CA2210799C (en) 2008-06-10
AP662A (en) 1998-08-19
CA2210799A1 (en) 1996-07-25
DE69635106T2 (de) 2006-06-08
NO973326D0 (no) 1997-07-18
AR002270A1 (es) 1998-03-11
ATE302777T1 (de) 2005-09-15
SK285329B6 (sk) 2006-11-03
EP0804436B1 (en) 2005-08-24
IL116831A0 (en) 1996-05-14
NO315558B1 (no) 2003-09-22
UA46001C2 (uk) 2002-05-15
UY25779A1 (es) 2000-08-21
WO1996022291A1 (en) 1996-07-25
IL116831A (en) 1998-10-30
KR100376074B1 (ko) 2003-06-02
AU702794B2 (en) 1999-03-04
HRP960024A2 (en) 1997-10-31
SI0804436T1 (sl) 2006-02-28
HU222993B1 (hu) 2004-01-28
EA000364B1 (ru) 1999-06-24
CN1179159A (zh) 1998-04-15

Similar Documents

Publication Publication Date Title
TR199700656T1 (xx) Guanin derivatlar�.
FR2733244B1 (fr) Systeme de stabilisants a base de derives de polyalkylpiperidine
FI933566A0 (fi) Nytt foerfarande foer framstaellning av 7-(substituerade)-9-((substituerad glycyl)amido)-6-demetyl-6-deoxitetracykliner
NO971538L (no) Purin- og guaninforbindelser som inhibitorer for PNP
TR199800011T1 (xx) Benzo$g] kuinolin t�revleri
AR038430A2 (es) Derivados de parahercuamida b
PT841928E (pt) Formulacao de libertacao prolongada de d-trep-metilfenidato
CA2189007A1 (en) Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
DE69709938D1 (de) N-benzylpiperidin- und tetrahydropyridin-derivate
BR0007643A (pt) Processo para obter ésteres de (nitroximetil) fenila de derivados de aspirina, e, (hidroximetil) feniléter de derivados de aspirina
MX9800412A (es) Preparacion de 3-hidroxipirazoles n-substituidos.
ES2152563T3 (es) Procedimiento para preparar derivados de dihidroxipirimidina.
ITMI922450A0 (it) Processo per la preparazione di un intermedio della sintesi organica
UA8017A1 (uk) Спосіб отримання похідних хінолінкарбонової кислоти
MX9801190A (es) Inhibidores de prolil endopeptidasa.
PT763047E (pt) Novo processo para a preparacao de nucleosidos
PT88364A (pt) Process for preparing novel hmg-coa reductase inhibitors
UY24327A1 (es) Derivados de cefalosporina
ITMI931264A1 (it) Processo per la sintesi della 9-(2-idrossietossimetil)- guanina
BR9609062A (pt) Processo para a síntese de benzo-tiofenos [B]
GR1001134B (el) Βελτιωμενη μεθοδος για χρησιμα παραγωγα διαζινυλπιπεριδινων.
ES2157331T3 (es) Procedimiento de produccion de un derivado de indolocarbazol.
ITMI931331A0 (it) Processo per la sintesi della 2-ammino-6-cloropurina
DK0566557T3 (da) 2- og 3-amino- og azidoderivater af 1,5- iminosukkere som antivirale forbindelser
ITMI941149A0 (it) Processo per la sintesi della 2-ammino -6- cloropurina